Sign In
Buy QLGN
$3.21
+0 (+0%)
At Close: Feb 17, 2026
Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023
04:30pm, Tuesday, 14'th Nov 2023
CARLSBAD, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers w
CARLSBAD, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers w
Poster Includes Preclinical Data on Pan-RAS Compounds Demonstrating Inhibition in Breast Cancer Models
Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023
08:30am, Wednesday, 27'th Sep 2023
Two p osters include data on potential clinical biomarkers and transcriptomic data associated with QN-302's mechanism of action
CARLSBAD, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers w
Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023
08:30am, Tuesday, 15'th Aug 2023
Investigational New Drug (IND) clearance transitions Qualigen from preclinical to clinical-stage company Company divests FastPack ® diagnostics business for approximately $5 mi llion in all cash tran
Investigational New Drug (IND) clearance transitions Qualigen Therapeutics from preclinical to clinical-stage company and d emonstrates leadership in G4-targeting therapies for areas of high unmet nee
Qualigen Therapeutics Divests FastPack® Diagnostics Business
08:15am, Monday, 24'th Jul 2023
All cash deal with Chembio Diagnostics, a US Subsidiary of the French Diagnostics Company BIOSYNEX, SA, solidifies Qualigen's strategic priority on therapeutics
Qualigen Therapeutics to Present Five Posters at the American Association for Cancer Research Annual Meeting 2023
09:05am, Wednesday, 15'th Mar 2023
CARLSBAD, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatmen
Qualigen Therapeutics Chief Executive Officer Michael Poirier Provides Letter to Stockholders
02:05pm, Wednesday, 01'st Feb 2023 GlobeNewswire Inc.
CARLSBAD, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatme
Qualigen Therapeutics Initiates Good Laboratory Practice (GLP) Toxicology Studies on QN-302
02:00pm, Tuesday, 24'th Jan 2023 GlobeNewswire Inc.
CARLSBAD, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatme
Qualigen Therapeutics Promotes Benedict M. Abugan to Vice President, Head of Diagnostics and Corporate Communications
02:02pm, Monday, 23'rd Jan 2023 GlobeNewswire Inc.
CARLSBAD, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatme
Qualigen Therapeutics Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid Tumors
02:10pm, Wednesday, 07'th Dec 2022 GlobeNewswire Inc.
CARLSBAD, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatme
Qualigen Therapeutics Announces Two Posters of Its RAS-Targeted Inhibitor Program at the National Cancer Institute
09:30am, Wednesday, 19'th Oct 2022
Fourth RAS Initiative Symposium Highlights Preclinical Data in Solid Tumor Models CARLSBAD, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sc
Qualigen Therapeutics to Present at LD Micro Main Event XV
09:30am, Tuesday, 18'th Oct 2022
CARLSBAD, Calif., Oct. 18, 2022 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers wi
